Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 56% Improvement Relative Risk c19hcq.org Ly et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ+AZ beneficial for COVID-19? Retrospective 226 patients in France Lower mortality with HCQ+AZ (p=0.02) Ly et al., Int. J. Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106219 Favors HCQ Favors control
Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, March-June 2020
Ly et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106219 (date from earlier preprint)
Ly et al., Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille,.., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106219 (date from earlier preprint)
Aug 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective analysis of retirement homes, HCQ+AZ >= 3 days mortality OR 0.37, p=0.02. 1690 elderly residents (mean age 83), 226 infected residents, 116 treated with HCQ+AZ >= 3 days.
Detection via mass screening also showed significant improvements (16.9% vs. 40.6%, OR 0.20, p=0.001), suggesting that earlier detection and treatment is more successful.
risk of death, 55.6% lower, RR 0.44, p = 0.02, treatment 18 of 116 (15.5%), control 29 of 110 (26.4%), NNT 9.2, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ly et al., 21 Aug 2020, retrospective, France, peer-reviewed, mean age 83.0, 21 authors, dosage 200mg tid days 1-10, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: International Journal of Antimicrobial Agents 56 (2020) 106219 Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: www.elsevier.com/locate/ijantimicag Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 2020 Tran Duc Anh Ly a,b, Didier Zanini c, Vincent Laforge c, Sylvie Arlotto d,e, Stephanie Gentile d,e, Helene Mendizabal d, Michael Finaud f, David Morel f, Olivier Quenette f, Priscilla Malfuson-Clot-Faybesse g, Alain Midejean h, Phuc Le-Dinh i, Gérard Daher i, Berengere Labarriere j, Anne-Marie Morel-Roux k, Alain Coquet l, Patrick Augier m, Philippe Parola a,b, Eric Chabriere b,n, Didier Raoult b,n, Philippe Gautret a,b,∗ a Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France IHU-Méditerranée Infection, Marseille, France Hospitalisation à Domicile (HAD), Hôpital de la Conception, Marseille, France d Service d’Evaluation Médicale, Hôpitaux Universitaires de Marseille Assistance Publique Hôpitaux de Marseille (APHM), Marseille, France e Aix Marseille Univ, School of medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of life Center, Marseille, France f Etablissement d’Hébergement pour Personnes Agées Dépendantes Saint-Barthélemy-Fondation Saint-Jean-de-Dieu, Marseille, France g Etablissement d’Hébergement pour Personnes Agées Dépendantes Korian Perier, Marseille, France h Etablissement d’Hébergement pour Personnes Agées Dépendantes Chevillon, Marseille, France i Etablissement d’Hébergement pour Personnes Agées Dépendantes La Joliette Marseille Groupe Colisée, Marseille, France j Etablissement d’Hébergement pour Personnes Agées Dépendantes Des Séolanes groupe Domusvi, Marseille, France k Etablissement d’Hébergement pour Personnes Agées Dépendantes Les Opalines La Roseraie, Marseille, France l Etablissements d’Hébergement pour Personnes Agées Dépendantes Aeria et Meissel, Marseille, France m Le Bataillon de marins-pompiers de Marseille (BMPM), Marseille, France n Aix Marseille Univ, MEPHI, Marseille, France b c a r t i c l e i n f o Article history: Received 6 October 2020 Accepted 1 November 2020 Keywords: COVID-19 SARS-CoV-2 Elderly resident Long-term care facility Mass testing Hydroxycloroquine a b s t r a c t Objectives: This study aimed to report the results of SARS-CoV-2 PCR-based screening campaigns conducted on dependent elderly residents (compared with staff members) in long-term care facilities (LTCFs) in Marseille, France, and the follow-up of positive cases. Methods: Data from 1691 elderly residents and 10 0 0 members of staff were retrospectively collected through interviewing the medical teams in 24 LTCFs and using the hospitals’ electronic health recording systems. Results: Elderly residents were predominantly female (64.8%) with a mean age of 83.0 years. SARS-CoV-2 detection among residents (226, 13.4%) was significantly higher than among staff members (87, 8.7%) (P < 0.001). Of the 226 infected residents, 37 (16.4%) were detected on a case-by-case basis due to their COVID-19 symptoms and 189 (83.6%) were detected through mass screening. Most (77.0%) had possible COVID-19 symptoms, including respiratory symptoms and signs (44.5%) and fever (46.5%); 23.0% were asymptomatic. A total of 116 (51.4%) patients received a course of oral hydroxychloroquine and azithromycin (HCQ-AZM) for ≥ 3 days; 47 (20.8%) died. Through multivariate..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit